Does the media refer more to PLYX or FENC?

In the previous week, Adherex Technologies had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 7 mentions for Adherex Technologies and 3 mentions for Polaryx Therapeutics. Adherex Technologies' average media sentiment score of 0.66 beat Polaryx Therapeutics' score of 0.25 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLYX or ENTA?

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 1.60 beat Polaryx Therapeutics' score of 0.25 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PLYX or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 10 mentions for Eyepoint Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.25 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Polaryx Therapeutics N/A N/A N/A

Does the media refer more to PALI or PLYX?

In the previous week, Palisade Bio and Palisade Bio both had 3 articles in the media. Palisade Bio's average media sentiment score of 1.31 beat Polaryx Therapeutics' score of 0.25 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IKT or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Polaryx Therapeutics N/A N/A N/A

Does the media prefer IKT or PLYX?

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 3 mentions for Polaryx Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.71 beat Polaryx Therapeutics' score of 0.25 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Polaryx Therapeutics (PLYX) Competitors

$1.99 -0.05 (-2.45%)

As of 09/3/2026 04:00 PM Eastern

Compare

PLYX vs. FENC, ENTA, EYPT, PALI, and IKT

Should you buy Polaryx Therapeutics stock or one of its competitors? Polaryx Therapeutics's main competitors and comparable companies include Adherex Technologies (FENC), Enanta Pharmaceuticals (ENTA), Eyepoint Pharmaceuticals (EYPT), Palisade Bio (PALI), and Inhibikase Therapeutics (IKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polaryx Therapeutics compare to Adherex Technologies?

Polaryx Therapeutics (NASDAQ:PLYX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Adherex Technologies had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 7 mentions for Adherex Technologies and 3 mentions for Polaryx Therapeutics. Adherex Technologies' average media sentiment score of 0.66 beat Polaryx Therapeutics' score of 0.25 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Polaryx Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Polaryx Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Adherex Technologies	-6.09%	-5.71%	-2.37%

Polaryx Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 285.26%. Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 35.46%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Polaryx Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

55.5% of Adherex Technologies shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Polaryx Therapeutics has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Adherex Technologies	$44.64M	9.86	-$9.74M	-$0.13	N/A

Summary

Polaryx Therapeutics beats Adherex Technologies on 10 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Polaryx Therapeutics (NASDAQ:PLYX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 1.60 beat Polaryx Therapeutics' score of 0.25 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Polaryx Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Polaryx Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 285.26%. Enanta Pharmaceuticals has a consensus target price of $19.50, indicating a potential upside of 39.09%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Polaryx Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Enanta Pharmaceuticals	$65.26M	6.26	-$81.89M	-$2.41	N/A

Summary

Polaryx Therapeutics beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Eyepoint Pharmaceuticals?

Polaryx Therapeutics (NASDAQ:PLYX) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Polaryx Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Polaryx Therapeutics' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Polaryx Therapeutics has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 285.26%. Eyepoint Pharmaceuticals has a consensus target price of $25.70, indicating a potential upside of 462.36%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

In the previous week, Eyepoint Pharmaceuticals had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 10 mentions for Eyepoint Pharmaceuticals and 3 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.25 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Polaryx Therapeutics beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Palisade Bio and Palisade Bio both had 3 articles in the media. Palisade Bio's average media sentiment score of 1.31 beat Polaryx Therapeutics' score of 0.25 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Polaryx Therapeutics	N/A	N/A	N/A

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Polaryx Therapeutics has lower revenue, but higher earnings than Palisade Bio. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,425.53	-$16.78M	-$0.48	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Palisade Bio currently has a consensus target price of $9.00, suggesting a potential upside of 340.10%. Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 285.26%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Palisade Bio is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Palisade Bio beats Polaryx Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Inhibikase Therapeutics presently has a consensus target price of $5.40, indicating a potential upside of 114.29%. Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 285.26%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has lower revenue, but higher earnings than Inhibikase Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,352.46	-$48.26M	-$0.43	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 3 mentions for Polaryx Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.71 beat Polaryx Therapeutics' score of 0.25 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Polaryx Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Inhibikase Therapeutics beats Polaryx Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$101.69M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-24.88	787.27	273.28	25.38
Price / Sales	N/A	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	9.05	12.33	12.89	6.14
Net Income	-$8.98M	$2.82B	$3.47B	$349.01M
7 Day Performance	-3.40%	2.60%	0.61%	-0.27%
1 Month Performance	-10.76%	6.96%	5.73%	0.68%
1 Year Performance	N/A	9.48%	25.37%	14.84%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	2.8083 of 5 stars	$1.99 -2.5%	$7.67 +285.3%	N/A	$101.69M	N/A	N/A	11
FENC Adherex Technologies	4.4017 of 5 stars	$12.27 +4.2%	$17.00 +38.5%	+41.6%	$412.64M	$44.64M	N/A	10	Positive News Insider Trade
ENTA Enanta Pharmaceuticals	1.9072 of 5 stars	$13.60 -1.4%	$19.50 +43.4%	+59.0%	$401.93M	$65.26M	N/A	160	Positive News
EYPT Eyepoint Pharmaceuticals	2.499 of 5 stars	$4.48 -3.2%	$28.11 +527.5%	-61.9%	$399.16M	$31.37M	N/A	120	Analyst Upgrade
PALI Palisade Bio	2.7361 of 5 stars	$2.00 -5.2%	$9.00 +350.0%	+215.4%	$367.71M	$250K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. FENC, ENTA, EYPT, PALI, and IKT

How does Polaryx Therapeutics compare to Adherex Technologies?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Palisade Bio?

Summary

How does Polaryx Therapeutics compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. FENC, ENTA, EYPT, PALI, and IKT

How does Polaryx Therapeutics compare to Adherex Technologies?

Does the media refer more to PLYX or FENC?

Is PLYX or FENC more profitable?

Do analysts prefer PLYX or FENC?

Do institutionals and insiders hold more shares of PLYX or FENC?

Which has higher valuation and earnings, PLYX or FENC?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Does the media favor PLYX or ENTA?

Is PLYX or ENTA more profitable?

Do analysts prefer PLYX or ENTA?

Do institutionals & insiders hold more shares of PLYX or ENTA?

Which has preferable earnings & valuation, PLYX or ENTA?

Summary

How does Polaryx Therapeutics compare to Eyepoint Pharmaceuticals?

Is PLYX or EYPT more profitable?

Which has higher valuation and earnings, PLYX or EYPT?

Do analysts prefer PLYX or EYPT?

Does the media prefer PLYX or EYPT?

Do insiders and institutionals hold more shares of PLYX or EYPT?

Summary

How does Polaryx Therapeutics compare to Palisade Bio?

Does the media refer more to PALI or PLYX?

Is PALI or PLYX more profitable?

Do institutionals & insiders have more ownership in PALI or PLYX?

Which has preferable earnings & valuation, PALI or PLYX?

Do analysts recommend PALI or PLYX?

Summary

How does Polaryx Therapeutics compare to Inhibikase Therapeutics?

Do analysts recommend IKT or PLYX?

Which has better valuation and earnings, IKT or PLYX?

Does the media prefer IKT or PLYX?

Do institutionals and insiders believe in IKT or PLYX?

Is IKT or PLYX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools